LEGN shorts retreat as borrow tightens ahead of November print

Legend Biotech heads into its November 10 earnings release with short sellers pulling back sharply, yet the borrow market telling a more complicated story underneath.

The most striking move this week is the rapid unwind of short positions. Short interest fell 15% in a single session on October 26, dropping to 8.5% of the free float from a recent peak above 10%. The weekly decline was also 15%, reversing a build that had pushed positions toward 20-million shares earlier in October. On paper, that looks like growing confidence in the CARVYKTI story. But the borrow market is moving in the opposite direction: availability tightened to just 29% this week, down from above 60% seven days earlier and from more than 130% in late September. The 52-week low availability reading is 24%, and the current level is close to it. That means the shares-to-borrow pool is shrinking fast even as positioned shorts are covering, a combination that does not straightforwardly read as bullish.

Cost to borrow remains low at 0.75%, up around 26% over the past month but in absolute terms still well below any squeeze-pressure threshold. Options traders are not pressing hard in either direction. The put/call ratio is 0.42, in line with its 20-day average of 0.42 and essentially a z-score of zero, placing it toward the bullish end of the 52-week range (the peak put demand hit 1.45 this year). Calls dominate the book, and there is no sign of defensive hedging building into earnings. Taken together, the positioning picture is one of short-side retreat rather than conviction buying: shorts are covering, calls are dominant, but the borrow pool is draining in ways that leave less room for new short entries if the print disappoints.

The Street remains constructive but has been steadily trimming targets. Barclays, JP Morgan, and RBC all lowered price targets in early October while keeping their ratings unchanged. Barclays is at $68 (Overweight), RBC at $56 (Outperform), and JP Morgan, the most cautious of the major names, at $33 (Neutral). The mean analyst target sits around $45.62, more than double the current price of $20.39, but that gap reflects the width of conviction rather than a consensus call. The bull case centres on CARVYKTI's Q2 global sales of $657 million, collaboration profits of $326 million, and the shift toward earlier-line use where 2L-4L patients now account for roughly 70% of volume. The bear case, particularly from TD Cowen (Hold, $24 target), focuses on bispecific and anito-cel competition, the J&J execution dependency, and pipeline assets LB1908 and LB2102 carrying low approval probabilities. The ORTEX short score at 76.7 out of 100 flags persistent short-side interest despite the recent covering, and the stock ranks in just the 4th percentile for short score, meaning it carries more bearish pressure than 96% of the universe.

One ownership detail is worth noting. FMR (Fidelity) added 3.2 million shares in the quarter ending September 30, lifting its stake to around 15% of shares outstanding, and BlackRock added roughly 650,000 shares in the same period. Both are passive-to-active managers adding on weakness, which at least signals the institutional bid has not vanished at current prices. No activist 13D is on the register; the only 13G filers are FMR and T. Rowe Price, the latter last filing in February 2025. The ORTEX Alt Data layer flags a spike in retail attention, with a Wikipedia-views z-score of 4.2 against the stock's own 90-day history, an attention signal rather than a revenue indicator, but one that tracks the stock's sharp 9% gain on the week.

The prior two earnings prints delivered muted day-one moves of roughly flat to down 1.5%, with the five-day window producing a wider range of minus 6.5% to plus 6.1%. With the next print on November 10 and availability in the borrow market continuing to tighten, the relevant question is whether CARVYKTI's Q3 revenue trajectory is accelerating fast enough to justify a price that still sits at half the Street's average target.